DailyIQ
|
Sector:HealthcareAll sectors
Last updated 1 hour ago

OSCR·Oscar Health, Inc.

$.
-. (-.%)
High
$22.98
Open
$22.75
Market Cap
6.83B
52W High
$25.58
Low
$21.70
P. Close
$22.64
P/E
-
52W Low
$10.69
Fwd P/E
16.41
Mean Target
-
Technical Score (1D)
100
BUY
News Sentiment
45
MIXED
Oscar Health shares are experiencing pressure today after the CFO sold $2.75 million in company stock, a development that could raise investor concerns about insider confidence. This follows news of a revenue shortfall in the first quarter, despite the company beating earnings expectations. The broader health insurance market faces potential headwinds from the expiration of enhanced Affordable Care Act (ACA) subsidies, which could impact insurer customer bases. Earlier this week, Oscar Health saw positive sentiment driven by robust first-quarter results, including 147% net income growth and 52% revenue expansion, alongside CMS fee cuts for ACA marketplaces. This strong performance has contributed to significant positive share price returns over the past year, leading to questions about whether the market has fully priced in this rapid growth. Technically, Oscar Health also recently experienced a golden cross, a bullish signal where the 50-day moving average crossed above the 200-day moving average, suggesting a potential positive short-term trend. Investors will be watching for sustained momentum following these recent developments and the potential impact of ACA subsidy changes on the company's customer acquisition and retention strategies.
Earnings Summary
Oscar Health, Inc. is a healthcare technology firm providing health plans to individuals, families, and employer groups, distinguishing itself through its integrated approach and the +Oscar platform that supports other healthcare entities. Operating in the Healthcare sector, specifically the Healthcare Plans industry, Oscar Health offers insurance plans and technology solutions, aiming to enhance engagement for healthcare providers and payers. In its most recent reported quarters, Oscar Health has shown mixed performance in earnings per share (EPS) but significant revenue growth. For Q1 2026, the company reported an EPS of $2.07 against an estimate of $1.10, and revenue of $4.65 billion against an estimate of $4.92 billion. This followed a Q4 2025 where EPS was -$1.24 (missed estimate of $1.04333) and revenue was $2.81 billion (missed estimate of $4.28 billion). Prior to this, Q3 2025 saw EPS of -$0.53 (beat estimate of -$0.58019) and revenue of $2.99 billion (no estimate provided), and Q2 2025 had EPS of -$0.89 (missed estimate of -$0.836) with revenue of $2.86 billion. The trend shows significant EPS volatility and revenue misses in the most recent periods, contrasting with a strong EPS beat in Q1 2026. Historically, Oscar Health has demonstrated substantial year-over-year revenue growth, but has experienced a pattern of missing analyst estimates for EPS in several recent quarters, notably Q4 2025 and Q2 2025, despite beating estimates in Q3 2025 and Q1 2026. Recent news indicates Oscar Health reported strong Q1 2026 financial results, exceeding expectations and reaffirming full-year 2026 guidance. The company also launched the Lucie Health Marketplace platform. Jefferies upgraded Oscar Health to a Hold rating from Underperform and raised its price target, suggesting a more neutral near-term outlook. Siddhartha Sankaran was appointed as the new independent Chair of the Board. Investors will be watching for continued execution against reaffirmed guidance, the impact of the Lucie Health Marketplace, and any further commentary surrounding leadership transitions. Key will be the company's ability to consistently meet revenue estimates and manage EPS performance in the upcoming quarters.

EPS

EstBeatMiss
$-1.74$-0.66$0.41$1.49$2.57Q1'25Q2'25Q3'25Q4'25Q1'26
QtrEstActual+/−
Q1'26$1.10$2.07+88.2%
Q4'25$1.04$-1.24-218.9%
Q3'25$-0.58$-0.53+8.7%
Q2'25$-0.84$-0.89-6.5%
Q1'25$0.81$0.92+13.9%

Revenue

EstBeatMiss
$2.5B$3.2B$3.9B$4.5B$5.2BQ1'25Q2'25Q3'25Q4'25Q1'26
QtrEstActual+/−
Q1'26$4.9B$4.6B-5.5%
Q4'25$4.3B$2.8B-34.5%
Q3'25 - $3.0B -
Q2'25 - $2.9B -
Q1'25 - $3.0B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

OSCR Stock Snapshot

OSCR is currently trading at $21.70, giving Oscar Health, Inc. a market cap of 6.83B. Today's range spans $21.70–$22.98, with shares opening at $22.75 and moving down $0.94 (4.2%) from the prior close. DailyIQ's technical score sits at 100/100 (BUY) with a news sentiment reading of 45/100.

Over the past year OSCR has traded between $10.69 and $25.58 - the current price is +103.0% off the 52-week low and -15.2% from the high.

Short interest can be a signal in itself for OSCR - at 6.83B in Healthcare market cap with a bullish technical setup (100/100, BUY) and neutral sentiment (45/100), a high short float turns into a potential catalyst. Price: $21.70 (in the upper portion of its 52-week range in $10.69–$25.58). If the technical momentum persists and shorts are forced to cover, the move can be multiples of what the signal alone would imply - a dynamic unique to small-cap names with the right setup.

The combination of a BUY technical signal (100/100) and neutral news sentiment (45/100) in a small-cap like OSCR (6.83B, Healthcare) creates the kind of setup that shows up in small-cap momentum screens used by growth-oriented funds. At $21.70 (in the upper portion of its 52-week range in $10.69–$25.58), the stock is not yet crowded — which means the entry risk-reward is better than it will be if the technical and sentiment setup persists and attracts wider institutional attention.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

0+ articles
Loading latest news…